A Phase 1 clinical trial to evaluate the effect of lemzoparlimab in combination with Rituxan in patients with relapsed or refractory advanced lymphoma and Non Hodgkin's lymphoma
Latest Information Update: 15 Dec 2021
At a glance
- Drugs Lemzoparlimab (Primary) ; Rituximab (Primary)
- Indications Lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Sponsors I-MAB Biopharma
- 09 Dec 2021 According to an I-MAB Biopharma Media release, the company will hold a call with investors at 8:00 a.m. EST on December 14 to provide an in-depth analysis of this trial.
- 31 May 2021 Status changed from planning to recruiting, according to an I-MAB Biopharma Media release.
- 18 May 2021 According to an I-MAB Biopharma Media release, patient enrollment in this study will be completed by Q4 2021 with the preliminary topline data expected thereafter.